NeuBase Therapeutics, Inc.

DB:O7P Stock Report

Market Cap: €1.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NeuBase Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of O7P?
Owner TypeNumber of SharesOwnership Percentage
Private Companies195,0535.2%
Individual Insiders235,7596.28%
Institutions753,38920.1%
General Public2,567,38968.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 121.9%.

Top Shareholders

Top 25 shareholders own 31.57% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.14%
Dietrich Stephan
230,512€78.5k0%no data
5.13%
Symetryx Corporation
192,481€65.6k0%no data
3.63%
DME Capital Management, LP
136,350€46.4k149%no data
2.92%
Barry Shiff Registered Retirement Savings Plan
109,508€37.3k0%no data
2.35%
Renaissance Technologies LLC
88,229€30.1k54.9%no data
2.18%
Greenlight Capital, Inc.
81,619€27.8k-40.1%no data
2.16%
Aleta Shiff Registered Retirement Savings Plan
80,973€27.6k0%no data
2%
Kershner Trading Group LLC, Asset Management Arm
74,861€25.5k0%1.76%
1.7%
Point72 Asset Management, L.P.
63,751€21.7k2%no data
1.25%
Carnegie Mellon University Endowment Arm
46,970€16.0k0%0.02%
0.51%
The Vanguard Group, Inc.
18,981€6.5k0%no data
0.42%
Jacob Asset Management of New York LLC
15,655€5.3k0%0.01%
0.41%
Prelude Capital Management, LLC
15,550€5.3k0%no data
0.41%
Geode Capital Management, LLC
15,482€5.3k0%no data
0.11%
UBS Asset Management AG
4,056€1.4k-93.8%no data
0.069%
Tower Research Capital LLC
2,572€876.15.07%no data
0.06%
Eric Richman
2,247€765.30%no data
0.04%
Dov Goldstein
1,500€510.90%no data
0.04%
Todd Branning
1,500€510.90%no data
0.021%
Merrill Lynch & Co. Inc., Banking Investments
791€269.40%no data
0.0094%
First Manhattan Co. LLC
353€120.20%no data
0.0041%
Royal Bank of Canada, Banking & Securities Investments
153€52.1-49%no data
0.0013%
Wells Fargo & Company, Securities and Brokerage Investments
50€17.00%no data
0.00077%
Wells Fargo & Company, Private Banking and Investment Banking Arm
29€9.80%no data
0.00059%
Securities America Advisors, Inc.
22€7.50%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/02 00:57
End of Day Share Price 2024/05/13 00:00
Earnings2023/03/31
Annual Earnings2022/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeuBase Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Whitney IjemGuggenheim Securities, LLC
Raghuram SelvarajuH.C. Wainwright & Co.